The present invention relates to novel, non-secosteroidal, sulfonate and
sulfonamide functional diaryl compounds with vitamin D receptor (VDR)
modulating activity that are less hypercalcemic than 1.alpha.,25
dihydroxy vitamin D3. These compounds are useful for treating bone
disease and psoriasis.